A5017558263- COVID-19 Clinical Research Studies
- Kawasaki Disease and Coronary Complications
- SARS-CoV-2 and COVID-19 Research
- Antibiotic Resistance in Bacteria
- Urinary Tract Infections Management
- Coronary Artery Anomalies
- Bacterial Identification and Susceptibility Testing
- Cystic Fibrosis Research Advances
- Antibiotic Use and Resistance
- Mechanical Circulatory Support Devices
- COVID-19 Impact on Reproduction
- Diabetes Management and Research
- Diabetes and associated disorders
- Antibiotics Pharmacokinetics and Efficacy
- Patient Satisfaction in Healthcare
- Neonatal and Maternal Infections
- Respiratory Support and Mechanisms
- Burkholderia infections and melioidosis
- Pediatric Urology and Nephrology Studies
- Plant Pathogenic Bacteria Studies
- Sepsis Diagnosis and Treatment
- Long-Term Effects of COVID-19
- Pancreatitis Pathology and Treatment
- Central Venous Catheters and Hemodialysis
- Antifungal resistance and susceptibility
Children's of Alabama
2020-2023
University of Alabama at Birmingham
2022
Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develop severe or critical illness. Guidance therefore needed regarding use agents with potential activity against acute respiratory syndrome 2 pediatrics.
Abstract Background Although coronavirus disease 2019 (COVID-19) is a mild infection in most children, small proportion develop severe or critical illness. Data describing agents with potential antiviral activity continue to expand such that updated guidance needed regarding use of these children. Methods A panel pediatric infectious diseases physicians and pharmacists from 20 geographically diverse North American institutions was convened. Through series teleconferences web-based surveys,...
In November 2020, the US Food and Drug Administration (FDA) provided Emergency Use Authorizations (EUA) for 2 novel virus-neutralizing monoclonal antibody therapies, bamlanivimab REGN-COV2 (casirivimab plus imdevimab), treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adolescents adults specified high-risk groups. This has challenged clinicians determine best approach use these products.A panel experts pediatric infectious diseases, diseases pharmacy, intensive care...
Immune-mediated lung injury and systemic hyperinflammation are characteristic of severe critical coronavirus disease 2019 (COVID-19) in adults. Although the majority acute respiratory syndrome 2 infections pediatric populations result minimal or mild COVID-19 phase infection, a small subset children develop even this with concomitant inflammation that may benefit from immunomodulation. Therefore, guidance is needed regarding immunomodulatory therapies setting COVID-19. This document does not...
Although many children's hospitals have established antimicrobial stewardship programs (ASPs), data-driven benchmarks for optimizing use across centers are lacking. We developed a multicenter quality improvement collaborative focused on sharing data reports and benchmarking to improve prescribing among hospitalized children.A national hospitals, Sharing Antimicrobial Reports Pediatric Stewardship (SHARPS), was in 2013. Characteristics of the their ASPs were obtained through standardized...
In children with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, virological characteristics and correlation disease severity have not been extensively studied. The primary objective in this study is to determine the between SARS-CoV-2 viral load (VL) infected age, severity, underlying comorbidities.
While diabetes is a risk factor for severe illness from acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults, there conflicting data surrounding the relationship between virus and diabetic disease process children.This case series aims to illustrate an increase incidence of types 1 mellitus (T1DM, T2DM) April - November 2020 at large tertiary care children's hospital examine characteristics adverse outcomes these children. In addition, two children with significant...
Abstract Introduction Respiratory infection with methicillin‐resistant Staphylococcus aureus (MRSA) is an increasing complication in cystic fibrosis (CF) that results accelerated lung function decline and mortality. Vancomycin considered a first‐line intravenous treatment agent for MRSA associated acute pulmonary exacerbations (APEs); however, rates of vancomycin intolerance resistance have been observed. These factors led to the exploration additional options treating APEs. Methods This...
The goals of antimicrobial stewardship programs (ASPs) are to optimize prescribing habits in order improve patient outcomes, reduce resistance, and hospital costs. Multiple society-endorsed guidelines government policies reinforce the importance ASP implementation. Effective can impact unique patients, hospitals, societal antibiotic-resistance burden. role subsequent success these has largely been reported adult population. Pediatric neonatal intensive care units present challenges for...
Abstract Background Use of mixed-oil (MO) intravenous fat emulsion (IFE) was shown to inhibit Candida albicans biofilm formation and overall rate catheter-related bloodstream infections (CR-BSIs) compared with soybean-oil (SO) IFE). We aimed delineate this inhibitory mechanism impact IFE choice on distribution fungal CR-BSIs. Methods Transcriptional profiling conducted C. grown in SO-IFE, MO-IFE, or SO-IFE capric acid. Overexpression strains shared down-regulated genes were constructed using...
Burkholderia cepacia complex (Bcc) is an opportunistic pathogen, posing little risk to healthy individuals. The presentation of Bcc can vary from a virtually asymptomatic chronic infection, acute, life-threatening necrotizing pneumonia, acute respiratory distress syndrome, and bacteremia (cepacia syndrome) associated with mortality rate up 75%. We present the successful treatment 17-year-old male granulomatous disorder who presented syndrome confirmed pneumonia using novel antimicrobial...
Abstract Cardiac outcomes of 131 children with multisystem inflammatory syndrome (MIS-C) were examined. The majority the cohort was male (66.4%) and half Black (49.6%). involvement evident in 25% at diagnosis. Favorable short- mid-term documented on follow-up, irrespective severe acute respiratory coronavirus 2 variants causing infection.
Abstract Background MIS-C is a hyper inflammatory condition following SARS-CoV-2 infection. Although COVID-19 infection rates and severity have varied based on circulating variants, it unclear if cardiac involvement in varies with different variants. The objective of this study to describe the children three waves infections. Methods Children hospitalized diagnosis were enrolled prospective observational study. Demographic, clinical, laboratory (troponin I B-type natriuretic peptide (BNP)),...